Type 2 diabetes
Conditions
Interventions
Intervention group:Proline gagliflozin tablets were given on the basis of conventional diabetes and hypertension treatment, taking 25 mg/dose once a day. Treatment was continuous for 8 weeks.
Sponsors
Luoyang Oriental People's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Diagnosed with type 2 diabetes according to the "Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes (2024 Edition)", and diagnosed with hypertension according to the "Chinese Guidelines for the Prevention and Treatment of Hypertension (2024 Revised Edition)"; 2. Glycated hemoglobin (HbA1c) <=11% or fasting blood glucose <=13.3 mmol/L; 3. Aged between 60 and 80 years old, regardless of gender; 4. Previously not treated with sodium-glucose cotransporter 2 inhibitors (SGLT2i), or discontinued SGLT2i for more than 7 days; 5. Patient's blood pressure is well controlled; 6. The original antidiabetic and antihypertensive regimen and medications have been used for more than 1 month prior to entering the study, and the determined treatment drugs and regimens will remain unchanged during the study period.
Exclusion criteria
Exclusion criteria: 1. Cardiac insufficiency, hepatic or renal insufficiency; 2. Urinary tract or genital tract infection; 3. Malignancy and chronic infection, psychiatric disorders, blood or immune system diseases, especially those requiring hormone therapy; 4. Severe diabetic complications/comorbidities, such as stroke, acute coronary syndrome, etc.; 5. Severe cardiovascular disease, surgical history; 6. Patients with isolated systolic hypertension, secondary hypertension, or a history of blood pressure controlled below 90/60 mmHg; 7. Use of glucagon-like peptide-1 receptor agonists or dipeptidyl peptidase 4 inhibitors; 8. History of hypersensitivity to drugs used in the study such as dapagliflozin propanediol or its excipients, or contraindications to the study drugs; 9. Subjects who, in the investigator's judgment, are unlikely to comply with the protocol, or have other severe physical or psychological conditions that may affect efficacy and safety.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Achievement of clinical control of glycated hemoglobin at 8 weeks of treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Fasting blood glucose after 8 weeks of treatment;Blood pressure control rate after 8 weeks of treatment; | — |
Countries
China
Contacts
Public ContactLi Suxia
Luoyang Oriental People's Hospital
Outcome results
None listed